Abstract
BackgroundThe burden of hospitalizations and mortality for hemoptysis due to bronchiectasis is not well characterized. The primary outcome of our study was to evaluate in-hospital mortality in patients admitted with hemoptysis and bronchiectasis, as well as the rates of bronchial artery embolization, length of stay, and hospitalization costs.MethodsThe authors queried the Nationwide Inpatient Sample (NIS) claims database for hospitalizations between 2016 and 2017 using the ICD-10-CM codes for hemoptysis and bronchiectasis in the United States. Multivariable regression was used to evaluate predictors of in-hospital mortality, embolization, length of stay, and hospital costs.ResultsThere were 8240 hospitalizations (weighted) for hemoptysis in the United States from 2016 to 2017. The overall in-hospital mortality was 4.5%, but higher in males compared to females. Predictors of in-hospital mortality included undergoing three or more procedures, age, and congestive heart failure. Bronchial artery embolization (BAE) was utilized during 2.1% of hospitalizations and was more frequently used in those with nontuberculous mycobacteria and aspergillus infections, but not pseudomonal infections. The mean length of stay was 6 days and the median hospitalization cost per patient was USD $9,610. Having comorbidities and procedures was significantly associated with increased length of stay and costs.ConclusionHemoptysis is a frequent indication for hospitalization among the bronchiectasis population. In-hospital death occurred in approximately 4.5% of hospitalizations. The effectiveness of BAE in treating and preventing recurrent hemoptysis from bronchiectasis needs to be explored.
Highlights
Non-cystic fibrosis bronchiectasis is a chronic suppurative lung disease characterized by chronic productive cough and episodic infectious exacerbations
Chronic airway inflammation and infection can lead to hemoptysis but life-threatening hemoptysis may be due to a rupture of a tortuous blood vessel [12]
There were a total of 8,240 weighted hospitalizations (1648 unweighted hospitalizations from a 20% stratified random sample of non-federal acute care hospitals in the United States (US)) for hemoptysis in persons with bronchiectasis in the study period
Summary
Non-cystic fibrosis bronchiectasis (hereafter referred to as “bronchiectasis”) is a chronic suppurative lung disease characterized by chronic productive cough and episodic infectious exacerbations. Hemoptysis is a well-known and feared complication of bronchiectasis, ranging from chronic small volumes to massive hemoptysis that can be life-threatening. Chronic airway inflammation and infection can lead to hemoptysis but life-threatening hemoptysis may be due to a rupture of a tortuous blood vessel [12]. Hemoptysis was a symptom in 23% of patients in a US bronchiectasis research registry [19]. The burden of hospitalizations and mortality for hemoptysis due to bronchiectasis is not well characterized. The primary outcome of our study was to evaluate in-hospital mortality in patients admitted with hemoptysis and bronchiectasis, as well as the rates of bronchial artery embolization, length of stay, and hospitalization costs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
